SQI Diagnostics Inc logo

SQD - SQI Diagnostics Inc Share Price

C$0.19 0.0  0.0%

Last Trade - 22/05/20

Micro Cap
Market Cap £30.9m
Enterprise Value £33.8m
Revenue £1.06m
Position in Universe 807th / 2658
Unlock SQD Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 December 2019, SQI Diagnostics Inc. revenues decreased 29% to C$207K. Net loss increased 15% to C$2M. Revenues reflect Product sales decrease of 40% to C$147K. Higher net loss reflects Laboratory cost and supplies increase of 88% to C$228K (expense), Finance costs increase of 47% to C$224K (expense), Professional and consulting fees increase of 25% to C$144K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


SQD Revenue Unlock SQD Revenue

Net Income

SQD Net Income Unlock SQD Revenue

Normalised EPS

SQD Normalised EPS Unlock SQD Revenue

PE Ratio Range

SQD PE Ratio Range Unlock SQD Revenue

Dividend Yield Range

SQD Dividend Yield Range Unlock SQD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SQD EPS Forecasts Unlock SQD Revenue
Profile Summary

SQI Diagnostics Inc (SQI) is a Canada-based diagnostics company. The Company develops multiplexed tests and automated systems for customers needing to measure a range of biomarkers in blood or other common sample types. It offers three different platforms sqidlite, sqid x and the siqdworks to run and analyze its microarray plates. Its Ig_plex microarrays have the ability to discriminate between individual isotypes of antibodies and antigens and proteins within a single well of a microarray. Its Ig_plex CHEX technology provides multiple in-microarray checks. It has three areas of focus: Testing for the drug development industry, Animal health testing, Human disease testing or deoxyribonucleic acid (DNA) diagnostic testing. In drug development testing, SQI provides technology and equipment for blood testing in clinical trials and pre-clinical research for developing various drugs. It applies its multiplexing technology to diagnostic tests used for customers in the animal health segment.

Last Annual September 30th, 2019
Last Interim December 31st, 2019
Incorporated September 11, 2003
Public Since February 9, 2005
No. of Shareholders: n/a
No. of Employees: 37
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange TSX Venture Exchange
Shares in Issue 276,785,535
Free Float (0.0%)
Eligible for
SQD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SQD
Upcoming Events for SQD
Wednesday 26th August, 2020 Estimate
Q3 2020 SQI Diagnostics Inc Earnings Release
Similar to SQD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.